PDT + triamcinolone shows promise as treatment for non-subfoveal CNV

Short-term results from a small study suggest combined verteporfin (Visudyne,Novartis) photodynamic therapy (PDT) with intravitreal triamcinolone meritsadditional investigation for the treatment of non-subfoveal CNV, said RichardF. Spaide, MD.

Related Videos

View All

Related Content

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

January 30th 2023

Related Content

---

Eyenuk gets greenlight to market AI screening system in European Union

Article

---

Commercial real estate and your practice, part two with Colin Carr

Podcast

---

Study: Retina specialists gain awareness of biosimilars

Article

---

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

Podcast

---

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

Article

---

Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases Workshop

Article